Objective To evaluate the efficacy and safety of poly ADP ribose polymerase (PARP) inhibitors for treating recurrent ovarian cancer.Methods The databases of Medline,Embase,Central and SinoMed were retrieved with the retrieval time from their establishment to September 2017;in addition the related reference literatures were manually retrieved.The randomized controlled trials (RCTs) of PARP inhibitors for treating recurrent ovarian cancer were included.The meta analysis was performed by using the RevMan 5.3 software.Results A total of 5 RCTs were included,including 1 160 cases in the experimental group and 679 cases in the control group.When compared with placebo,PARP inhibitors significantly improved the progression-free survival [HR=0.34,95％CI(0.30,0.40),P＜0.01] and overall survival [HR=0.73,95％CI(0.55,0.96),P=0.025],and increased objective response rate [RR=2.56,95％CI(1.17,5.59),P=0.020].The addition of PARP inhibitors to chemotherapy reduced the risk of disease progression [HR =0.51,95 ％CI (0.34,0.77),P =0.001].However,there were no statistically significant differences in overall survival [HR=1.17,95％CI(0.79,1.73),P=0.440] and objective response rate [RR=1.11,95％CI(0.86,1.42),P =0.420] between the PARP inhibitors plus chemotherapy group and the chemotherapy alone group.The administration of PARP inhibitors was associated with a significantly increased risk of serious anemia,fatigue,nausea and vomiting.Conclusion PARP inhibitors could improve the progression-free survival outcome in recurrent ovarian cancer.

Objective To evaluate the association of vaginal dysbiosis and infertility.Methods Cohort studies, case-control studies and cross-sectional studies were searched in electronic databases, including MEDLINE,EMBASE and SinoMed(from inception to October 2017);in addition, the reference lists of included studies and similar reviews were handsearched.These studies investigating the correlation between vaginal dysbiosis and infertility were included.The Meta-Analysis was performed by RevMan 5.3 software.Results 1 724 records were retrieved by the search; from those,9 cross-sectional studies were included,comprising 3 367 participants(1 702 in infertility group and 1 665 in control group).The likelihood of vaginal dysbiosis in infertility group is higher than that of control group[OR=3.15,95% CI (1.57,6.32), P=0.001].Conclusions The available evidence suggests that vaginal dysbiosis was associated with the incidence of infertility.However, further case-control studies or cohort studies are required to confirm or refute these findings.(Chin J Lab Med,2018,41:281-286)